Medical Condition News

RSS

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Generex Biotechnology Corporation (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).

17 Mar 2010

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.

17 Mar 2010

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Aegis Analytical Corp., the leading provider of Enterprise Manufacturing Intelligence software, announced today that Human Genome Sciences, Inc. will deploy Aegis’ Discoverant® as its data management, analytics and reporting solution in the scale-up and production of BENLYSTA™ (belimumab), an investigational drug for the treatment of systemic lupus that has successfully completed Phase 3 trials.

17 Mar 2010

Genentech submits ACTEMRA sBLA to FDA

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for ACTEMRA® (tocilizumab) for the prevention of structural joint damage (as assessed by radiograph) and improvement in physical function in adults with moderately to severely active rheumatoid arthritis (RA).

17 Mar 2010

Heart disease patients may benefit from secondary preventive care

Research has shown that heart disease patients who make lifestyle improvements, take recommended medications and control risk factors such as high cholesterol and high blood pressure can prevent heart disease from worsening.

17 Mar 2010

Cryotherapy offers potential treatment options for breast cancer patients

Interventional radiologists have opened the door to an encouraging potential future treatment for the nearly 200,000 women who are diagnosed with breast cancer in the United States each year: image-guided, multiprobe cryotherapy.

17 Mar 2010

Despite accomplishments and improvements, cancer remains too common disease in the U.S.

Although there have been achievements in the battle against cancer, including a decrease in the rate of death and new diagnoses, cancer remains one of the leading causes of death in the U.S., with a need for continued improvement in the areas of prevention, detection and treatment, according to a commentary in the March 17 issue of JAMA, a theme issue on cancer.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain.

17 Mar 2010

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages.

17 Mar 2010

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

The Fonds de la recherche en santé du Québec in partnership with the Ministère de la Santé et des Services sociaux and Pfizer Canada, is announcing the creation of the Pfizer-FRSQ-MSSS Chronic Disease Fund. Established with an investment of $5 million from Pfizer Canada, this research grant program, coordinated by the FRSQ, is open to Quebec-based researchers who work in collaboration with health professionals.

17 Mar 2010

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.

16 Mar 2010

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met®, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos®, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

16 Mar 2010

Adam 3XL addresses young people with weight problem

Adam 3XL (published by Trafford) by Dr. Martin Noelke is a novel about basketball, love, friendship ... and some nutritional guidelines for weight reduction in the long run. It's the story of a one-time high school basketball all-star who stops exercising and packs on the pounds after losing both of his parents. Dr. Noelke infuses his expertise as a general practitioner and nutrition specialist into the story to send a message to today's youth about health.

16 Mar 2010

PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.

16 Mar 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).

16 Mar 2010

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging (MPI) agent. The study of nine patients compared rest-stress flurpiridaz F 18 PET MPI, with rest-stress technetium-99m (Tc-99m) labeled single photon emission computed tomography (SPECT) for the detection and evaluation of coronary artery disease (CAD).

16 Mar 2010

Patient enrollment in Spinal Restoration' Phase III study of Biostat System now underway

Spinal Restoration, Inc. announced today that patient enrollment in the company’s Phase III study of the Biostat System for the treatment of discogenic chronic low back pain is now underway. The study, which will be conducted at 15 U.S. clinical sites, is one of only a few multi-center, randomized, blinded, placebo-controlled trials of a nonsurgical treatment for discogenic low back pain ever to be conducted.

16 Mar 2010

Shaking hands with robotic arm could help stroke patients learn to use arms again

Shaking hands with a robotic arm could be a new way to help stroke patients learn to use their arms again. Researchers writing in BioMed Central's open access Journal of NeuroEngineering and Rehabilitation report a pilot trial of the 'Braccio di Ferro' (Iron arm) robot in 10 patients.

16 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Medical Condition News

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Genentech submits ACTEMRA sBLA to FDA

Heart disease patients may benefit from secondary preventive care

Cryotherapy offers potential treatment options for breast cancer patients

Despite accomplishments and improvements, cancer remains too common disease in the U.S.

Key cellular defect in protein synthesis can lead to cancer susceptibility

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical

Adam 3XL addresses young people with weight problem

PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Patient enrollment in Spinal Restoration' Phase III study of Biostat System now underway

Shaking hands with robotic arm could help stroke patients learn to use arms again

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News